Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it was added to the Russell 3000 Index as part of the annual reconstitution of the Russell indexes, which occurred on June 26, 2009.

"Investors recognize the Russell 3000 as an established benchmark for tracking investment performance, market movements and market trends. We are pleased that Micromet has been added to the Russell 3000 Index and expect that it will increase our visibility in the investment community," said Buck Phillips, Senior Vice President and Chief Financial Officer of Micromet.

Annual reconstitution of Russell's U.S. indexes captures the largest U.S. stocks as of the end of May, determined by total market capitalization. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to the Russell indexes. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell 3000 and other Russell indexes is available at www.russell.com/Indexes/performance/def
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 News ... India devoted to genome-based research for ... Genomics (NIBMG) is taking a bite out of oral ... among males in India with the ... solutions from DataDirect Networks (DDN). , To fuel its ...
(Date:9/23/2014)... , Sept. 23, 2014   GenoSpace , ... comprehensive suite of tools to enable the broad use ... announced that it has been awarded Phase I of ... from the National Institutes of Health (NIH) to enable ... Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
(Date:9/23/2014)... Dr. Williams says, “Find The Black Box ... a three phase process that can lead to the ... would go far beyond anything previously imagined. First everyone ... healthcare.” , “Every effort to improve the quality of ... progress throughout that system because all of the experts ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2
... of Allowance of European Patent Application Covering Its Core Natural ... Applications Protection Rights to All Cytokine ... ... (GO), a biotechnology,company dedicated to the discovery and development of improved ...
... 24 Researchers at 28th annual,National Academy ... City this,weekend will present data to help ... breast cancer survivors affected by,"Chemobrain". Chemobrain is ... types of cancer. It is associated with ...
... 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX:ONY), a ... products for the treatment of cancer, today,announced that ... scheduled to present at the 7th Annual BIO ... 2008 at 8:00 a.m. Pacific Time., A ...
Cached Biology Technology:GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 2GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 3GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 4Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain' 2
(Date:9/23/2014)... a lot greener thanks to a novel technique developed ... solar energy to accelerate tailings pond reclamation efforts by ... light source to treat oil sands process affected water ... and James Bolton have found that using the sunlight ... as efficiently but at a much lower cost. , ...
(Date:9/23/2014)... The National Institutes of Health will award funds to ... Drug Screening program to improve ways of predicting drug ... to refine existing 3-D human tissue chips and combine ... complex functions of the human body. Led by the ... will support 11 institutions at $17 million in 2014 ...
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... This release is available in German . ... disk currently consists of about 3 million magnetic atoms. Researchers ... memory with one bit per molecule. By an electric pulse, ... magnetic state and a low-conductive, non-magnetic state. This novel correlation ...
... in most developing countries to meet the United Nations, ... from hunger by 2015 compared with 1990 levels, according ... and weight, published today in the Lancet . ... improved overall since 1985, one in five infants and ...
... medicine for Parkinson,s disease, by investigating signs of the ... respond to drug treatments. The study was funded by ... skin cells from patients with genetically inherited forms of ... found that neurons derived from individuals with distinct types ...
Cached Biology News:Nature: Molecule changes magnetism and conductance 2Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates 2Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates 3Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Biology Products: